MIRA Pharmaceuticals (MIRA) Insider Pratt Buys 50,000 Shares

Whalen Matthew Pratt recently increased his position in MIRA Pharmaceuticals, Inc. (NasdaqCM: MIRA). According to a recent filing, Pratt acquired 50,000 shares of the company on June 12, 2026. This move was part of a larger cluster of activity at the healthcare firm, where multiple individuals took new positions on the same date.

Insider Buying and Selling at MIRA Pharmaceuticals, Inc.

The transaction by Whalen Matthew Pratt was just one of several similar moves reported on June 12, 2026. Denil Nanji Shekhat acquired 50,000 shares in two separate transactions, and Matthew Paul Del Giudice also added 50,000 shares in two distinct filings. Additionally, Edward Clouston Macpherson purchased 50,000 shares. None of these trades were conducted under a Rule 10b5-1 plan, which is a tool insiders often use to schedule trades in advance. The lack of such a plan means these were discretionary decisions made by those close to the company's daily operations.

MIRA Stock Performance and Valuation

Shares of MIRA Pharmaceuticals are priced at $0.93 as of Tuesday. The stock has seen a wide range over the past year, trading as low as $0.60 and as high as $2.45. While the current price is slightly above its 50-day moving average of $0.80, it has not yet reclaimed its 200-day moving average of $1.08. Because the company is still in its development phase, it does not currently report a P/E ratio, as it has not yet reached profitability.

Analysts Set New Price Targets

Wall Street analysts have expressed a positive outlook on the company's prospects. On September 17, 2026, Maxim Group initiated coverage on MIRA Pharmaceuticals with a Buy rating. The firm set a price target of $3.50, which is significantly higher than the stock's current trading level. This matches the broader consensus among the one analyst providing an opinion, who maintains a Buy recommendation and a $3.50 average price target.

Drug Development Pipeline

MIRA Pharmaceuticals is a pre-clinical stage company focused on treating brain-related disorders. Its main project, Ketamir-2, is a next-generation treatment that has finished Phase 1 clinical trials. The company is also looking into MIRA-55 for anxiety and early-stage dementia, along with SKNY-1, which targets obesity and nicotine addiction. These insiders are buying in as the company moves these neuroscience programs through the expensive and complex testing process.

Future Outlook

Investors will likely watch for the next round of clinical results to see if the company's neuroscience treatments can meet their goals. While the recent insider buying shows confidence from those within the company, these filings are backward-looking and may not reflect the current positions of the individuals involved. The company's ability to fund its research and reach the next stage of clinical trials remains a primary focus for the market.